Curative Options for Early HCC: Resection, Ablation and the Case for Transplant

After HCC resection on a normal liver, patients are generally placed on lenvatinib long-term. After transplant, there is no separate adjuvant chemotherapy; instead, immunosuppression is adjusted to tacrolimus plus everolimus rather than the standard tacrolimus and mycophenolate, since everolimus is associated with a lower recurrence risk. For cholangiocarcinoma with nodal or vascular invasion, patients are referred to medical oncology for cisplatin or gemcitabine-based adjuvant therapy, usually once they have recovered, six to twelve weeks later, from preoperative jaundice and cholangitis.

No, this is not typical of the Pringle manoeuvre itself. Needing a stent afterwards points to bile duct involvement: a narrowed biliary confluence after a right hepatectomy, a bile leak that progressed to a stricture after a hepaticojejunostomy, or compromised duct vascularity following preoperative radiotherapy. The Pringle manoeuvre alone may raise liver enzymes, but it should not cause obstructive jaundice.

For HCC after resection or an interventional procedure, MRI is favoured over repeated CT scans, both to limit cumulative radiation and contrast exposure and because MRI catches smaller lesions earlier, while they are still resectable or eligible for salvage transplant. Cholangiocarcinoma follow-up similarly relies on CT or MRI rather than ultrasound, alongside tumour markers, AFP and PIVKA-II for HCC, CA19-9 for cholangiocarcinoma.

Intent comes first. Even in India, transplant is offered at only a handful of government centres, with growth coming mainly from the private sector. Beyond intent, a new programme needs mentorship from teams already trained in transplant so that skills transfer gradually, buy-in across radiology, anaesthesia, critical care and hepatology rather than a purely surgeon-driven effort, and infrastructure including a strong interventional radiology service, phasic CT and MRI, and an apheresis machine for ABO-incompatible transplants. Management has to be fully behind the programme, because it takes far more time and effort than routine GI or hepatobiliary surgery.

Dr. George asked to review the actual scan before a specific recommendation, but for a resectable tumour around 3 to 3.5 centimetres, his general advice was not to force a diagnosis upfront: resect with a clear margin and send the specimen for histopathology. At that size, liver function or parenchymal loss is unlikely to be a concern, so surgery can proceed before, rather than after, a biopsy.

Cirrhosis is a pre-malignant condition. Removing or ablating today's visible tumour, whether by resection, microwave or TACE, does not remove the diseased liver tissue that produced it. Even after complete ablation, there is roughly a 70 percent chance over the next five years that another tumour will develop from the same liver.

Sometimes, through what is called a salvage transplant, but by the time a second tumour appears, vascular invasion may have developed and can take transplant off the table altogether. This risk is part of the argument for offering transplant upfront in eligible patients.

No. Multifocal tumours that still fall within transplant criteria can be offered transplant on the same basis as a single lesion, provided the overall disease burden qualifies.

Resection and ablation remove the tumour but leave the underlying cirrhotic liver in place, so the tissue that produced the first tumour remains capable of producing another. A transplant replaces that entire diseased liver, removing the source of recurrence rather than just the tumour itself.